17:34 EDT Moleculin Biotech files to sell common stock, warrants, no amount given
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Biotech Advances AML Treatment After FDA Meeting
- Moleculin Biotech completes End of Phase 2 meeting with FDA for Annamycin
- Moleculin Biotech Announces Promising Annamycin Trial Results
- Moleculin Biotech reports data from Phase 1B/2 (MB-106) clinical trial
- Moleculin Biotech files $200M mixed securities shelf